**Schisandra chinensis** Peptidoglycan-Assisted Transmembrane Transport of Lignans Uniquely Altered the Pharmacokinetic and Pharmacodynamic Mechanisms in Human HepG2 Cell Model

Charng-Cherng Chyau¹, Yaw-Bee Ker², Chi-Huang Chang¹, Shiau-Huei Huang¹, Hui-Er Wang², Chiuang-Chi Peng³, Robert Y. Peng¹,₄,*

¹Research Institute of Biotechnology, Hungkuang University, Shalu County, Taichung City, Taiwan, ²Department of Food And Applied Technology, Hungkuang University, Shalu County, Taichung City, Taiwan, ³Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, ⁴Research Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan

**Abstract**

*Schisandra chinensis* (Turz Baill) (S. chinensis) (SC) fruit is a hepatoprotective herb containing many lignans and a large amount of polysaccharides. A novel polysaccharide (called SC-2) was isolated from SC of MW 841 kDa, which exhibited a protein-to-polysaccharide ratio of 0.4089, and showed a characteristic FTIR spectrum of a peptidoglycan. Powder X-ray diffraction revealed microcrystalline structures within SC-2. SC-2 contained 10 monosaccharides and 15 amino acids (essential amino acids of 78.12% w/w). In a HepG2 cell model, SC-2 was shown by MT and TUNEL assay to be completely non-cytotoxic. A kinetic analysis and fluorescence-labeling technique revealed no intracellular disposition of SC-2. Combined treatment of lignans with SC-2 enhanced the intracellular transport of schisandrin B and deoxyschisandrin but decreased that of gomisin C, resulting in alteration of cell-killing bioactivity. The Second Law of Thermodynamics allows this type of unidirectional transport. Conclusively, SC-2 alters the transport and cell killing capability by a "Catcher-Pitcher Unidirectional Transport Mechanism".

**Introduction**

The primary function of polysaccharides is supposed only to assist tissue hydration and increase tissue resilience [1,2]. Pharmacologically, polysaccharides exhibit a diversity of uses including the drug transport improver [3], sustaining medicine transport [4], serving as an anchorage site for drug delivery liposomes [5], and enhancing the water solubility of carotenoids [6]. Hyalurronan, which was originally determined to act as an intercellular glue, was recently found to be a very potent intracellular signaling agent associated with multiple drug resistance [2], immunity and oncology [7,8].

*Schisandra chinensis* Turz Baill of the Magnoliaceae (*Wuweizi* in Chinese) (SC) is widely used as a valuable phytomedicine in China, Korea, and Japan to treat dysfunctional livers, lungs, hearts, and kidneys [9] and for chemical/viral hepatitis [10,11]. Dibenzo- 
cyclooctadiene lignans isolated from SC (abbreviated as SCLs) include schizandrin, deoxyschisandrin (schisandrin A, SA), gomisin, schisandrol B, y-schisandrin, wuweizisu B and C, and schisantherin C [12]. It is worth noting that the lignan compositional profile may depend on the separation technology [13].

Recently, SCLs like SA, Schisandrin B (SB) and gomisin C (GmC) have been well indicated to exhibit potent hepatoprotectives, anti-inflammatory, antitumor, antivirus, anti-HIV, immunomodulators, and antioxidative properties [9,11,14–19]. By inhibiting P4503A4 activity, schisandrol A and gomisin A were shown to affect cellular drug metabolism and uptake. Biological studies indicated that an extract of SC seeds enhanced the hepatic glutathione (GSH) antioxidant/detoxification system and facilitated both processes in the livers, consequently considered to be a promising agent for improving phase I oxidative metabolism in CCl4-damaged livers [20]. Moreover, compound SB-sesamin preparation reveals a prominent in vivo hepatoprotective effect [21].

Recently, the bioactivity of soluble polysaccharide of *Schisandra* fruits was found to have potent immunomodulating properties, like improving the weight of immune organs and enhancing the phagocytic activity of peritoneal macrophages [22]. Yan et al. demonstrated a rather promising synergistic hepatoprotective effect of SCLs when co-administered with *Astragalus* polysaccharides [23]. Previously, we found the peptidoglycan (named SC-2) to be biologically inactive against the HepG2 cells (unpublished
data). However, since SC-2 is water soluble in nature and decoction process has been always preferred for many Chinese Medicinal Preparations, we hypothesize that SC-2 with certain unknown mechanism might favor the therapeutic effect of SCLs. To verify this, the therapeutic effect of a serial model of SC-2, either used alone or in combination with individual SCLs, was extensively explored.

**Materials and Methods**

**Isolation and purification of dibenzocyclooctadiene lignans**

Desiccated sample SC fruits were purchased from Sun Ten Pharmaceutical Corp. (Taipei, Taiwan, ROC). Ten grams of desiccated fruits were extracted three times with 95% ethanol; each time 100 ml was extracted for 30 min in a sonication-assisted extractor. We have described the detailed methods in Text S1.

---

**Figure 1. Chemical structures of liganas isolated from *S. chinensis* fruits.** Gomisin C, deoxyschisandrin and schisandrin B isolated from the *S. chinensis* fruits. Structures of (+)deoxyschisandrin and (−)schisandrin B are depicted from Gnabre et al. (2010) [27]. Structure of gomisin C is depicted from Wang et al., (1994) [36].

doi:10.1371/journal.pone.0085165.g001
High-performance liquid chromatographic (HPLC)/electrospray ionization (ESI)/tandem mass spectrometry (MS/MS) analyses

Separation of the dibenzocyclooctadiene lignans was conducted on a Luna C18(2) column (i.d. = 2.00 x 150 mm, thickness = 3.0 μm) and a guard column (i.d. = 10 x 3 mm, Phenomenex Inc., Torrance, CA., U.S.A.) using an HPLC system consisting of a Finnigan Surveyor module separation system and a photodiode-array (PDA) detector (Thermo Electron Co., MA., U.S.A.). The next elution process and instrument setting was carried out according to La Torre et al. [24]. We have described the detailed methods in Text S1.

Fourier transform infrared (FTIR) analyses of isolated lignans

The lignans SA, SB and GmC were separately desiccated under a vacuum at 40°C for 16 h, respectively mixed with KBr powder (IR grade) at a ratio lignan: KBr = 1: 100 (w/w) and fabricated into tablets. The tablet was scanned with Shimadzu 8400S FTIR 460 (Shimadzu, Tokyo, Japan) spectrophotometer against the KBr blank at 400–4000 cm⁻¹ and a resolution of 2 cm⁻¹. Each sample was repeatedly scanned at least 10 times to assure the precision of the data. We have described the detailed methods in Text S1.

Solvent extraction of crude polysaccharides from SC

The method for extraction of crude polysaccharides from SC (SC-CP) was carried out according to Ker et al. [25]. We have described the detailed methods in Text S1.

Purification of crude polysaccharides from SC

Further isolation and purification of SC-CP were conducted with gel permeation chromatography (GPC) carried out according to Ker et al. [25] (be referred to Text S1). The yield of the purified product of the second fraction of SC-polysaccharide was 3.58%w/w (denoted as SC-2). We have described the detailed methods in Text S1 [26,31].

Characterization of the molecular weight and the molar extinction coefficient with high-performance size exclusion chromatography-tandem UV-visible and evaporative light scattering detection (HPSEC-UV-ELSD)

The HPSEC-UV-ELSD analysis was conducted to determine the molecular weight of SC-2. We have described the detailed methods in Text S1.

X-ray powder diffraction (powder XRD) of SC-2

Desiccated purified SC-2 powder was macerated to fine, homogenous consistency and subjected to an X-Ray diffraction
FTIR analyses of purified SC-2 and pure lignans+SC-2
To measure the combined IR spectra, pure SC-2 alone was used as reference blank. The other combined formula were prepared by mixing each lignan with SC-2 at equimolar ratio, i.e. for SA+SC-2: 2 mL of SA solution (1.04 mg in 25 mL)+2 mL of SC-2 solution (1 mg mL$^{-1}$). For SB+SC-2: 2 mL of SB (4 mg in 25 mL)+2 mL of SC-2 (4 mg mL$^{-1}$); and for GmC+SC-2: 2 mL of GmC solution (5.2 mg in 25 mL)+2 mL of SC-2 solution (4 mg mL$^{-1}$) were used. We have described the detailed methods in Text S1.

Monosaccharide composition of SC-2
The method for analyzing the monosaccharide composition was based on previous work [25,26]. We have described the detailed methods in Text S1 [25,35].

Amino acid composition in the protein moiety of SC-2
The method for analyzing the amino acid composition was according to previous work of Ker et al. [25]. We have described the detailed methods in Text S1 [25].
2 mL of DMEM medium. After incubated for 24 h at 37°C, FITC-SC-2 at 0.01, 0.1, 1.0, 10.0, and 25 μg mL⁻¹ were added and incubated to investigate the dose- and time–dependent effects on the disposition of SC-2. We have described the detailed method in Text S1 [28,29].

Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay

A TUNEL assay using the Fluorescein Apoptosis Detection Kits (Roche Applied Science, Indianapolis, IN, USA) was carried out according to the manufacturer’s instructions by Borisov et al. [30]. We described the detailed methods in Text S1 [31].

Statistical analysis

Data obtained in the same group were analyzed by an analysis of variance (ANOVA) and Student’s t-test with computer statistical software SPSS 10.0 (SPSS, Chicago, IL, USA). Statistical Analysis System (2000) software was used to analyze the variances, and Duncan’s multiple-range test was used to test the significance of difference between paired means. The significance of the difference was judged by a confidence level of p, 0.05.

Results

HPLC and ESI/MS/MS analysis of GmC Deoxyschisandrin (SA) and SB

The retention times of GmC, SA and SB (Fig. 1) in HPLC were 19.17, 29.07 and 31.69 min (Fig. 2) and their molecular weights were 536.6, 415.6 and 400.5, respectively (Fig. S1).

Characterization of SC-2

The purified soluble polysaccharide, named hereafter SC-2, showed an overall yield 3.58% (Fig. 3A, Table 1). SC-2 exhibited a MW 841 kDa (Fig. 3B) and molar extinctions 1.0260 × 10⁷ M⁻¹ cm⁻¹ and 1.766 × 10⁷ M⁻¹ cm⁻¹ at 280 nm and 490 nm, respectively (Fig. 3A). It contained 28.20 wt% protein and 68.97 wt% carbohydrate, yielding a ratio protein/carbohydrate = 0.4089 (Table 1). The sugar portion of SC-2 contained 10 monosaccharide species (Table 1). Their contents (in mol%) were fucose (28.64), rhamnose (14.64), arabinose (13.74), xylose (13.32), glucose (11.12), allose (8.34), ribose (4.61), talose (2.13), mannose (1.84) and myo-inositol (1.29) respectively, but galactose was completely absent (Table 1).

SC-2 comprised 15 kinds of amino acids. The major ten were (in % w/w): valine (10.34), leucine (15.80), isoleucine (14.29), methionine (1.98), proline (0.09) + hydroxyproline (1.96) ( = 2.05), phenylalanine (21.54) + tyrosine (2.94) ( = 24.48), cysteine (8.63), and histidine (17.15). The total essential amino acids amounted to 80.3% w/w (Table 1). The FTIR (KBr) νmax (cm⁻¹) spectrum showed many characteristic absorption bands, such as 3384.91 (νO-H, s, broad, polyhydroxyl hydrogen bonding), 3144.07, 3087.17 (νC-H, s), 2857.64 (νC-H, CH₃, m), 1734.17 (νC=O, m), 1647.02 (νC=O, amide, s), 1602.9, 1457.27 (δN-H, amide, s), 1339.61 (νC-O, amide, m), 1151.54 (νC-O, alcohol, s), 1100~1010 (νC-O, β-pyranoside, s), 1075.35 (νC-O, ester, s), 1006.88 (νC-O, ether, s), 952.87, 854.49 (δC-H, alkene, s), 768.66, 761.70 (δC-O, β-glycosidic linkage, w) and 680–760 (δC-H, aromatic, s)(Fig. 3C).

The powder XRD pattern revealed three 2θ peaks, i.e. 2θ = 42.216° with an intensity of 3644; 2θ = 51.1398° with an intensity of 3938; and 2θ = 72.66393° with intensity of 11190.

### Table 1. The compositional analysis of the glycoprotein SC-2 purified from S. chinensis fruits.

| Overall yield of purified SC-2, %w/w | 3.58 |
| Mean molecular weight, kDa | 841 |
| **Proximate analysis (mol%)** | |
| Total carbohydrate content | 68.97 |
| Crude protein content | 28.20 |

| Monosaccharide and amino acid composition of SC-2 |
|---|---|---|
| Rhamnose | 14.64 | Alanine | 0.18 |
| Fucose | 28.97 | Glycine | 0.40 |
| Ribose | 4.61 | Valine | 10.34 |
| Arabinose | 13.74 | Leucine | 15.80 |
| Xylose | 13.32 | Isoleucine | 14.29 |
| Allose | 8.34 | Proline | 0.09 |
| Talose | 2.13 | Methionine | 1.98 |
| Mannose | 1.84 | Glutamic acid | 0.38 |
| Galactose | n.d. | Hydroxyproline | 1.96 |
| Glucose | 11.12 | Phenylalanine | 21.54 |
| Myo-inositol | 1.29 | Cysteine | 2.60 |
| Lysine | 8.63 | Tyrosine | 2.94 |
| Aspartic acid | 1.72 | | |
| Histidine | 17.15 | | |

n.d.: not detected.
doi:10.1371/journal.pone.0085165.t001
Figure 4. FTIR spectra of the purified free lignans and the lignans+SC-2. Purified free deoxyschisandrin (upper panel) and deoxyschisandrin+SC-2 (lower panel) (A). Purified free schisandrin B (upper panel) and schisandrin B+SC-2 (lower panel) (B). And purified free gomisin C (upper panel) and gomisin C+SC-2 (lower panel) (C). In measuring of the combined IR spectra, equimolar amount of each was used: for deoxyschisandrin+SC-2: 2 mL of deoxyschisandrin solution (1.04 mg/25 mL)+2 mL of SC-2 solution (1 mg/mL). For schisandrin B+SC-2: 2 mL of schisandrin B (4 mg/25 mL)+2 mL of SC-2 (4 mg/mL). And for gomisin C+SC-2: 2 mL of gomisin solution (5.2 mg/25 mL)+2 mL of SC-2 solution (4 mg/mL) were used. The mixture was respectively mixed thoroughly with KBr (IR grade) (in 1:100 w/w), dried at 40 °C under vacuum for 16 h, fabricated into KBr tablets and subjected to FTIR scanning using Shimadzu FTIR 460 (Shimadzu, Tokyo, Japan). Each sample was repeatedly scanned for at least 10 times to assure the precision of the data.

doi:10.1371/journal.pone.0085165.g004

giving the specific diffraction angles at θ1 = 21.108°, θ2 = 25.569°, and θ3 = 36.331°, respectively (Fig. 3D).

FTIR and UV-Vis- ESI-MS- ESI-MS-MS characterization of the isolated lignans

For free SA: UV λmax (nm): 234, 254 (sh); ESI(+)-MS (m/z): 417 [M+H]+ (Fig. S1).

IR (KBr) νmax (cm⁻¹): 2990.73, 2925.15, 2876.92, 2830.63 (νC-H, CH₃, s), 1574.93, 1498.74, 1268.24 (phenolic νC-O, s), 1166.01, 1100.43, 1049.31, 1035.81, 1007.84 (νC-O, etheric, s), 990.48, 951.65 (δC-H, s, 2 peaks) (Fig. 4A, upper panel).

For free SB: UV λmax (nm): 234, 254 (sh); ESI(+)-MS (m/z): 401 [M+H]+ (Fig. S1).

IR (KBr) νmax (cm⁻¹): 2970.00, 2938.38, 2830.00 (νC-H, CH₃, s), 1616.4 (aromatic νC=C-H, s), 1498.74, 1268.24 (phenolic νC-O, s), 1198.80, 1150.58, 1106.21, 1096.57, 1047.38, 1037.74 (etheric νC-O, s), 926.83, 957.22 (δC-H, s, 2 peaks) (Fig. 4B, upper panel).

For free GmC: UV λmax (nm): 236, 258 (sh); ESI(+)-MS (m/z): 537 [M+H]+ (Fig. S1). IR (KBr) νmax (cm⁻¹): 3600.00 (νO-H, alcohol s), 3234.73 (νO-H, phenolic s, m broad H-bonding), 2948.29, 2882.71, 2842.20 (νC-H, s), 1718.63 (νC=O, s), 1617.37, 1598.08, 1582.63, 1501.63 (νC=C, aromatic, s), 1382.04, 1333.82 (νO-H, phenolic, s, 2 peaks), 1282.71, 1250.88, 1216.16, 1178.55, 1143.83, 1109.11, 1098.50, 1073.42, 1057.99 (νC=O, etheric, s), 949.01, 927.95 (δC-H, alkene, s), 818.81 (δC-H, polystyrene substituted aromatic, s) and 720.44 (δC-H, C6-monosubstituted aromatic, s) (Fig. 4C, upper panel).

FTIR spectra of the combined lignans plus SC-2

Surprisingly, we found the FTIR spectra of the combined lignans+SC-2 (Fig. 4) to be rather similar to that of SC-2 (Fig. 2C) alone.

For SA+SC-2, IR (KBr) νmax (cm⁻¹): 3384.92 (νO-H, s, broad, polyhydroxyl hydrogen bonding), 2925.15 (νC-H, CH₃-O, m), 1750 (νC=O, esteric, s), 1608–1630 (νC=O, amide, m) 1420 1400 (νC-N, amide, m), 1360 (νC-O, amide, m), 1200 (νC-O, phenolic, s), 1150, 1105 (νC=O, alcoholic, s), 1105, 1023 (νC-O, β-pyranoside), 768.34, 761.28 (δC-O, β-glycosidic linkage, w), 760–690 (δC=H, aromatic, disappeared or masked by SC-2) (Fig. 4A, lower panel).

For SB+SC-2, IR (KBr) νmax (cm⁻¹): 3400.30 (νO-H, s, broad, polyhydroxyl hydrogen bonding), 2938.65 (νC-H, CH₃-O, m), 2385.30, 2379.24 (νC=CH = N=, m), 1740.33 (νC=O, s), 1615.80 (νC=H, conjugated alkene, s), 1400.02 (νC-N, amide, s), 1160.50, 1030.34 (νC-O, ether, s), 760–690 (δC=H, aromatic, disappeared or masked by SC-2) (Fig. 4B, lower panel).

For GmC+SC-2, IR (KBr) νmax (cm⁻¹): 3485.26 (νO-H, s, broad, polyhydroxyl hydrogen bonding), 2948.59 (νC-H, CH₃-O, m), 2480.00, 2300.30 (νC=CH = N=, m), 1724.20 (νC=O, esteric, s), 1150.58, 1105.00, 1022.80 (νC-O, s), 760–690 (δC=H, aromatic, disappeared or masked by SC-2) (Fig. 4C, lower panel).
Effect of SC-2 on the cell viability of HepG2 cells

In medium containing 10% FBS, when treated with SC-2 at dosages 0.0297, 0.0595, 0.1189, 0.2378, 0.4756, 0.9512, and 1.9024 mM, respectively, the cell viability was seen still retaining at a level >80%, indicating the totally nontoxic behavior of SC-2 to HepG2 cells. At higher doses (0.9512, 1.9024 mM), a slightly declined cell viability occurred, suggesting a masking or plugging effect of SC-2 on the cell membrane (Fig. 5D).

Pharmacokinetic behavior of lignans in HepG2 cells

The uptake rates of free Shisandra lignans by HepG2 cells greatly differed from those combined with SC-2. For SB and SA, the uptake rates were apparently elevated by presence of SC-2. On the contrary, GmC showed a lower uptake rate (Table 2). Worth noting, free SA uniquely revealed a relatively delayed uptake rate that was totally not seen for the others (Table 2). In contrast, the uptake process was relatively shorter for both GmC and SA. Their peak points in uptake rates reached at or around 30 min (Table 2). Intracellular GmC was rapidly consumed up at 30 min for GmC and at 60 min for SA. The intracellular decay rate coefficient was \(1.092 \times 10^{-6} \text{ L mmol}^{-1} \text{ min}^{-1}\) for both GmC and SA (Table 2). A relatively longer uptake time was required by SB, which remained at \(1.429 \times 10^{-6} \text{ L mmol}^{-1} \text{ min}^{-1}\) even at 60 min (Table 2). The total amounts delivered from the extracellular to the intracellular compartments in the presence of SC-2 were (in decreasing order) SB, SA, GmC, corresponding to 91 ± 5 mM (at 60 min) > 77 ± 5 mM (at 15 min) = 27 ± 1 μM (at 30 min), respectively. For comparison, the respective order of the free lignans was: 82 ± 3, 63 ± 6 and 27 ± 1 μM. Interestingly, in the presence of SC-2 the uptake of GmC was significantly retarded (Table 2).

Pharmacodynamic behavior of lignans in HepG2 cells

Behaviors of HepG2 cells responding to these three lignans varied greatly depending on the dose, time of incubation, and the presence or absence of SC-2. At 48 h, free SB alone showed activated cell proliferation within doses of <0.16 mM (Fig. 5A). In the presence of SC-2, this activation disappeared (Fig. 5B). A similar phenomenon was seen for GmC (Fig. 5A & 5B), but not for
Table 2. Enhanced lignan uptake rate mediated by glycoprotein SC-2.

| Incubation time, (min) | Schisandrin B | Schisandrin B+SC-2a |
|------------------------|---------------|---------------------|
|                        | Uptake (μM)   | Decay rate constant, k1 (min⁻¹) | Uptake (μM) | Decay rate constant, k2 (L·mmol⁻¹·min⁻¹) |
| 0                      | 47b           | -                    | 46b         | -                                   |
| 5                      | 54±2          | 0.0140b              | 58±2        | 2.016×10⁻⁵b                         |
| 15                     | 68±3          | 0.0140               | 82±2        | 2.016×10⁻⁵                          |
| 30                     | 76±3          | 0.0053               | 86±4        | 2.269×10⁻⁶                          |
| 60                     | 82±3          | 0.0020               | 91±5        | 1.429×10⁻⁶                          |
| 90b                    | 86b           | 0.0013b              | 93b         | 5.865×10⁻⁷b                         |
| 120b                   | 82b           | -0.0013b             | 89b         | -1.092×10⁻⁶b                        |

*Values obtained by extrapolation.

Table 3. The cytotoxicity and HepG2 cell killing-capability of dibenzocyclooctadiene lignans in the presence and absence of its coexisting glycoprotein SC-2.

| Incubation time, h | Treatment                 | IC50, mM         | Killing capability, cells/mLb |
|--------------------|---------------------------|------------------|------------------------------|
| 48                 | Schisandrin B             | 0.55±0.06        | 1.11×10⁷ cells/mL (within 0.16–1.28 mM) |
|                    | Schisandrin B+SC-2        | 0.41±0.03        | 1.82×10⁷ cells/mL (at <0.64 mM) |
|                    | Gomisin C                 | 0.64±0.01        | 1.46×10⁷ cells/mL (at >0.16 mM) |
|                    | Deoxyschisandrin          | 0.59±0.02        | 1.73×10⁷ cells/mL            |
|                    | Gomisin C+SC-2            | 0.51±0.02        | 1.58×10⁷ cells/mL (average of two phases) |
|                    | Deoxyschisandrin+SC-2     | 0.15±0.04        | 4.29×10⁷ cells/mL (at <0.32 mM) |

bDose of SC-2 (MW: 841 kDa): 1 mg/mL (= 1.1891×10⁻³ mM) (*p<0.05; **p<0.01).

PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e85165
The SC-2 peptidoglycan was not transportable through the HepG2 cell membrane
SC-2 was totally nontoxic when used alone at a wide range of dosages (Fig. 5A), implying that free SC-2 was not mobilized into HepG2 cells. The fluorescent technology revealed the FITC-SC-2 molecules exclusively remained on the outer membrane of HepG2 cells even after 30 min of contact. No apparent difference was seen from the dose effect (Fig. 6A). However, the time-effect showed distinct higher accumulation of SC-2 on cell membrane (Fig. 6B).

TUNEL Assay
Free lignans were shown to be very effective in inducing apoptosis of HepG2 cells. DNA fragmentation was clearly perceivable by the TUNEL assay (Fig. 7A). In the presence of SC-2, the number of apoptotic cells was seen to have significantly increased (Fig. 7B).

Thermodynamic consideration of the transport process
To give a clear image of the role of SC-2 in the transport process for lignans, we proposed the diagrammatic model shown as Figure 8, which demonstrates the transport model of lignans through HepG2 cell membrane in the presence and absence of SC-2. It was assumed that the conformation of SC-2 was specifically altered when submerged onto the outer membrane of target cells, concomitantly, the free energy change declined to ΔG<0. The membrane-bound SC-2 specifically accumulated the lignans and pumped them into the intramembranous space. The cytosolic lignan concentration was thus rapidly raised to a higher level than the original extracellular concentration. Supposedly, GmC bearing an OH-group at position 7 (Fig. 1) could be more tightly arrested by SC-2. To quantify the magnitude of free energy changes, we defined two paths that transported lignans (Fig. 9), i.e. the path 1, in the absence of SC-2; and the path 2, in the presence of SC-2. In reality, path 1 is the common passive transport of lignans in the absence of SC-2. In path 1, the initial bulk fluid concentration of lignans (initial concentration C0) was passively transported a distance of X1 through the bulk fluid (reaction constant k1) and the cell membrane (thickness X2, reaction constants k2) to reach the inner membrane where due the membrane barrier the concentration dropped sharply to the effective innermembraneous concentration C1m, which was then moved into the cytoplasmic compartment and degraded (reaction constant k3) to C1mK at the reaction site of intracellular compartment (Fig. 9). Path 2 is the SC-2-assisted transport in which lignans in the bulk fluid (concentration, C0) were rapidly taken up by SC-2 already conjugated with the outer membrane (through a distance X1, reaction constant k1), where the outer membrane concentration rapidly dropped to C0m. Due to the “actively” pumping effect of SC-2, the intramembraneous lignan concentration was rapidly raised to C1m (through a distance of membrane thickness X2, reaction constant k2), which, on moving along the inner membrane barrier, abruptly dropped down to C1mK and simultaneously transferred into the cytoplasmic compartment and soon degraded to attain the final concentration C1mK at the reaction site (reaction constant k3).

The elucidation for thermodynamic mathematical model is shown in Text S1. From the initial total extracellular concentrations and the extracellular and the intracellular concentrations at the pseudoequilibrium state (Table 2), the estimated parameters

At 48 h, the respective killing capabilities were found to be 2.93×10^5 cells/mM, 1.46×10^5 cells/mM and 3.94×10^5 cells/mM when used alone. The combined use with SC-2 obviously altered the cytotoxic effects to 1.71×10^5 cells/mM, 1.73×10^5 cells/mM and 4.29×10^5 cells/mM, respectively for SB, and GmC and SA (Table 3). However at 72 h, the killing capabilities of free SB and free GmC were only comparable to those at 48 h. Conversely, SC-2 astonishingly significantly enhanced the cytotoxicity of GmC and SA to 3.94×10^5 cells/mM and 7.50×10^5 cells/mM, respectively (Table 3, Fig. 5A & 5B).

The elucidation for thermodynamic mathematical model is shown in Text S1. From the initial total extracellular concentrations and the extracellular and the intracellular concentrations at the pseudoequilibrium state (Table 2), the estimated parameters
were obtained. The peak concentration was the highest for SB followed by GmC and SA (Table 4). By following the model presented in Figure 8 and Figure 9, the magnitude of the stepwise free energy change for each transport step was calculated (Table 5, see Text S1), from which the overall free energy change exemplified by the largest $\Delta G_3$ of SA (Table 2, Table 4) was achieved (Table 6).

Figure 7. TUNEL assay for HepG2 cells. Cells treated with free lignans (A), and lignan plus SC-2 (B). Cells were induced for 24 h, then PI staining and TUNEL assay were carried out. Results were examined under a fluorescence microscope (×400).
doi:10.1371/journal.pone.0085165.g007
Figure 8. Diagrammatic model showing the transport of *S. chinensis* lignans through the HepG2 cell membrane in the presence and absence of peptidoglycan SC-2. The conformation of SC-2 was specifically altered when submerged onto the outer membrane of target cells, concomitantly, the free energy change declined to ΔG<0. The membrane-bound SC-2 specifically accumulated the lignans and pumped them into the intramembrane space. The cytosolic lignan concentration was thus rapidly raised to a higher level than the original extracellular concentration. Supposedly, Gomisin C bearing an OH-group at position 7 (Fig. 1) could be more tightly arrested by SC-2.

As can be expected, the other overall free energy changes would also remain at values of ΔG_{average} = -∞ (Table 6).

**Discussion**

The powder XRD (Fig. 3D) revealed SC-2 to be high pure microcrystalline lattice structures with characteristic intra-lattice dimensions of d₁ = 2.139 Å, d₂ = 1.786 Å, and d₃ = 1.300 Å. Speculatively, the strongest diffraction of 0₂ could be due to diffraction from the main plane with alpha helical units lining up to elicit an inter-unit distance of 1.300 Å. While the other two distances, d₁ and d₂, may have been due to diffractions at secondary minor lattice planes. The specific molar extinction coefficients, the characteristic ratio of proteins to carbohydrates (= 0.4089) and the strong hydrogen bonding and amide absorption bands at 1768.66 cm⁻¹ and 1761.78 cm⁻¹ (δC=O, β-glycosidic linkage, w) evidenced the characteristic nature of a peptidoglycan (Fig. 3C).

SC-2 was named ‘rhamnolucosan’ herein due to its unusual high fucose and rhamnose contents. The strong absorption at 280 nm implied the presence of huge amount of aromatic amino acids [32]. The exceptionally large amount of essential amino acid content (80.3%) implicated the traditional medicinal use of SC-2 as a hepatoprotective agent (attributed to cysteine and methionine) and the building blocks for the active sites or signaling sites (usually contributed by tyrosine, cysteine, and histidine) [33] (Table 1).

On the other hand, the apparently perceivable difference in FTIR absorption spectra GmC, SB, and SA could be due to the exocyclic methylene between C₁₂ and C₁₃ in both SB and GmC and the benzoyl ester at C6 of GmC. Similar results were reported by Ma et al. [34]. To our astonishment, the FTIR spectra of the pure SC-2 (Fig. 3C) and the lignan+SC-2 appeared extremely alike (Figs. 4A–4C, lower panels), underlying the occurrence of strong intermolecular interaction between lignans and SC-2 due to complete entrapment of lignans into SC-2 macromolecule.

Figure 9. Two different transport mechanisms with detailed concentration changes along the paths. In path 1, the initial bulk fluid concentration of lignans (initial concentration C₀) was passively transported a distance of X₁ through the bulk fluid (reaction constant k₁) and the cell membrane (thickness X₂, reaction constants k₂) to reach the inner membrane where due the membrane barrier the concentration dropped sharply to the effective intramembrane concentration C_{im}, which was then moved into the cytoplasmic compartment and degraded (reaction constant k₅) to C_{cm} at the reaction site of intracellular compartment (Fig. 9). Path 2 is the SC-2-assisted transport in which lignans in the bulk fluid (concentration, C₀) were rapidly taken up by SC-2 already conjugated with the outer membrane (through a distance X₁, reaction constant k₆), where the outer membrane concentration rapidly dropped to C_{om}. Due to the “actively” pumping effect of SC-2, the intramembrane lignan concentration was rapidly raised to C_{im} (through a distance of membrane thickness X₂, reaction constant k₆), which, on moving along the inner membrane barrier, abruptly dropped down to C_{cm} and simultaneously transferred into the cytoplasmic compartment and soon degraded to attain the final concentration C_{cm} at the reaction site (reaction constant k₅).

Biologically, SC-2 was entirely non-cytotoxic, while the slight decline in viability found for doses ≥800 μg/mL could have been due to the membrane-masking or -plugging exerted by SC-2 (Fig. 5, right lower panel).

Pharmacokinetically, the uptake rates of both SB and SA were apparently enhanced, conversely, GmC significantly retarded by SC-2 (Table 2). To interpret this, we assumed that the uptake of lignans obeyed first-order kinetics with respect to the free *Schisandra* lignan when used alone (eq. 1), whereas it obeyed a second-order kinetic in the presence of SC-2 (eq. 2):

\[ \frac{d[C]}{dt} = k_1 [C] \]  

(1)

\[ \frac{d[C]}{dt} = k_2 [C][S] \]  

(2)

where C is the concentration of SC lignans (μmol L⁻¹), t is the duration of incubation time (min), and S is the amount of SC-2 present in the reaction mixture (herein SC-2 = 1 mgmL⁻¹ or 1.1891 μmol L⁻¹). The parameters k₁ and k₂ are first- and the second-order uptake rate coefficients, respectively. The calculated uptake kinetic parameters are listed in Table 2. As shown, in the
### Table 4. Estimation of the parameters at status of pseudo equilibrium.

| Parameter          | Initial total extracellular concentration | Extracellular concentration (mM) | Intracellular concentration, Ls (mM) |
|--------------------|------------------------------------------|----------------------------------|--------------------------------------|
| [SC-2]             | 1 mg/mL (1.1891×10⁻³ mM)                | 0.0                              | 0.0                                  |
| [Mouter]           | [Mouter] >> [SC-2], hence [Mouter]      | [Mouter] >> [SC-2], hence [Mouter] | -                                    |
| [SC-2-Mouter] Ls   | 1.1891×10⁻³ mM                          | 1.1891×10⁻³ mM                   | 0.0                                  |
| C<sub>m</sub><sup>b</sup> | C<sub>m</sub> = 0.1 mM                  | -                                | (peak concentration)<sup>c</sup>    |
| Schisandrin B      | C<sub>m</sub> = 0.1 mM                  | C<sub>am</sub> = 0.007 mM        | C<sub>ma</sub><sup>c</sup> = 0.093 mM |
| Gomisin C          | C<sub>m</sub> = 0.1 mM                  | C<sub>am</sub> = 0.081 mM        | C<sub>ma</sub><sup>c</sup> = 0.019 mM |
| Deoxyyschandrin    | C<sub>m</sub> = 0.1 mM                  | C<sub>am</sub> = 0.085 mM        | C<sub>ma</sub><sup>c</sup> = 0.015 mM |
|                    | Assume C<sub>ma</sub><sup>c</sup>      | -                                | -                                    |
| [SC-2-Mouter] Ls   | 1.1891×10⁻³ mM                          | 1.1891×10⁻³ mM                   | 0.0                                  |
| C<sub>m</sub><sup>c</sup> | -                                       | -                                | -                                    |
| Schisandrin B      | -                                       | -                                | 0.005 mM                            |
| Gomisin C          | -                                       | -                                | 0.005 mM                            |
| Deoxyyschandrin    | -                                       | -                                | 0.005 mM                            |

<sup>a</sup>SC-2: MW = 841 kDa. 1 mg/mL = 1.1891×10⁻³ mM.

<sup>b</sup>The concentration of SC-2 was very small compared to that of outer membrane, hence [Mouter] was considered to be constant and designated K.

<sup>c</sup>Values obtained by extrapolation to zero time zero.

<sup>d</sup>C<sub>mE</sub>: estimated from Fig. 6.

### Table 5. Magnitude of parameters related with the free energy changes during the transport of lignans in the absence or presence of SC-2.

| Parameters          | Values of change in free energy, kcal/mol |
|---------------------|------------------------------------------|
|                    | ΔG<sub>0,1</sub> | ΔG<sub>0,2</sub> | ΔG<sub>0,3</sub> | ΔG<sub>0,4</sub> |
| [SC-2]<sup>a</sup> | -0.0             | -                 | -                 | -                 |
| [Mouter]<sup>b</sup> | Constant K      | -                 | -                 | -                 |
| [SC-2-Mouter], M    | -1.1891×10⁻⁶    | -1.1891×10⁻⁶      | -                 | -                 |
| [Ls]<sup>c</sup>    | -                | 9.988×10⁻⁴        | -                 | -                 |
| [SC-2-Mouter]-Ls, M | -1.1891×10⁻⁶    | -1.1891×10⁻⁶      | -                 | -                 |
| C<sub>m</sub><sup>c</sup> | -                | -                 | -                 | -                 |
| Schisandrin B       | -                | -                 | 46×10⁻⁶           | 46×10⁻⁶           |
| Gomisin C           | -                | -                 | 10×10⁻⁶           | 10×10⁻⁶           |
| Deoxyyschandrin     | -                | -                 | 55×10⁻⁶           | 55×10⁻⁶           |
| C<sub>am</sub><sup>c</sup> | -                | -                 | -                 | -                 |
| Schisandrin B       | C<sub>am</sub> = 7×10⁻⁶ |                |                  | -                 |
| Gomisin C           | C<sub>am</sub> = 81×10⁻⁶ |              |                  | -                 |
| Deoxyyschandrin     | C<sub>am</sub> = 85×10⁻⁶ |              |                  | -                 |
| C<sub>ma</sub><sup>c</sup> | -                | -                 | -                 | -                 |
| Schisandrin B       | C<sub>ma</sub><sup>c</sup> = 93×10⁻⁶ |            |                  | -                 |
| Gomisin C           | C<sub>ma</sub><sup>c</sup> = 19×10⁻⁶ |            |                  | -                 |
| Deoxyyschandrin     | C<sub>ma</sub><sup>c</sup> = 15×10⁻⁶ |            |                  | -                 |
| C<sub>mE</sub><sup>d</sup> | -                | -                 | -                 | -                 |
| Schisandrin B       | 5×10⁻⁶           |                  |                  | -                 |
| Gomisin C           | 5×10⁻⁶           |                  |                  | -                 |
| Deoxyyschandrin     | 5×10⁻⁶           |                  |                  | -                 |

<sup>a</sup>SC-2: MW = 841 kDa. 1 mg/mL = 1.1891×10⁻³ mM.

<sup>b</sup>The concentration of SC-2 was very small compared to that of outer membrane, hence [Mouter] was considered to be constant and designated K.

<sup>c</sup>Values obtained by extrapolation to zero time zero.

<sup>d</sup>C<sub>mE</sub>: estimated from Fig. 6.

doi:10.1371/journal.pone.0085165.t004
doi:10.1371/journal.pone.0085165.t005
presence of SC-2, the initial uptake rate constants (in L mmoles⁻¹ - min⁻¹) for SB, GmC and SA were 2.016 x 10⁻⁵, 5.046 x 10⁻⁶, and 1.261 x 10⁻⁵, respectively. A similar trend was also perceivable in free lignans but to a lesser extent (Table 2).

Worth noting, free SA uniquely revealed a relatively delayed uptake rate compared to those of GmC and SA. Intracellular concentrations of GmC were rapidly consumed up at 30 min for GmC and at 60 min for SA, both similarly yielding intracellular decay rates -1.092 x 10⁻⁶ L mmoles⁻¹ - min⁻¹ (Table 2), as contrast, the uptake of SB required much longer time. While in the presence of SC-2, the uptake of GmC was significantly suppressed (Table 2). The reason could be attributed to the retardation effect of SC-2 on the benzoyl esteric and C7-OH of GmC (Fig. 1). Over time, the total delivery rates became with the order SB > SA > GmC. Speculatively, the therapeutic indication of whole SC would be mostly depending on SB (Table 2).

Pharmacodynamically, the improved IC₅₀ values in time- and dose-dependent manner apparently implied that the enhanced transport of SB (Gomisin N) and GmC had been affected by SC-2 (Table 3, Fig. 5A & 5B). A previous report indicated the respective IC₅₀ values to be 0.043 and 0.336 mM with respect to human colorectal cancer cell line HT-29 [35]. As contrast, the IC₅₀ values for HepG2 cells were 0.19 mM for free SA and 0.15 mM for combined SC with SA, indicating cell-specific drug-susceptibilities.

Now the question arises: How did SC-2 affect the pharmaco-kinetik and pharmacodynamic outcomes of SC-lignans? To solve this issue, the FITC fluorscence technique was applied. Amazingly, labeled SC-2 was shown to have been completely un-mobilized into the cell membrane (Fig. 6A & 6B).

As was described in “Materials and methods”, FITC-SC-2 was added at 0.01, 0.1, 1.0, 10.0, and 25 lmol L⁻¹, which respectively corresponded to final concentrations of 0.0025 to 6.25 lmol L⁻¹. These amounts elicited approximate coverage rates (number of fmoles of FITC-SC-2 per HepG2 cell) of 3.0 x 10⁻⁵ to 7.5 x 10⁻² fmoles cell⁻¹. Taking the Avogadro’s number (6.02 x 10²³ molecules/mole) into account, the respective coverage rates became 1.81 x 10⁴ to 4.52 x 10⁵ FITC-SC-2 particles/cell, underlying the fuzzy appearance (Fig. 6B). Thus, in order to obtain a clearer image, we adopted concentrations much lower than those used for the MTT assay (Figs. 5A, Fig. 6A, 6B). More importantly, results distinctly revealed SC-2 molecules to be preferentially adhered onto the outer membranes of HepG2 cells (Fig. 6A, 6B), consistent with the widely cited [36,37]. Literature elsewhere indicated that SA with two methoxy groups respectively located at positions C12 and C13 (Fig. 1) could show the most cytotoxic behavior (i.e. the lowest IC₅₀ value) compared to GmC and SB (Gomisin N) [37,38] (Table 3). The latter two compounds exhibit an exocyclic methylene (-O-CH₂-O-) linkage instead of two methoxy groups (Fig. 1) [36,37], indicating exocyclic methylene linking C12 and C13 to be cytotoxicity attenuation-related. Supposedly, the C12 and C13 methoxy groups hindered the SA transport. Conversely, the exocyclic methylene (-O-CH₂-O-) linkage favored the rapid transport of SB and GmC (Table 2). Strong bioactivity can be attained by lignans structurally without ester group at C-6 and a hydroxyl group at C-7 or an exocyclic methylene chain between C12 and C13, but with an R-biphenyl configuration (Fig. 1, Table 3) [37]. Worth noting, 6(7)-dehydroschisandrol A, a derivative of SA, showed the highest activity (IC₅₀, 2.1 µM) as a platelet-activating factor antagonist [38].

SB (Gomisin N) was shown to increase the resistance of mitochondria to calcium ion-induced disruption, effectively preventing the apoptosis of hepatic cells under stressful conditions [39,40]. TUNEL assay indicated the approximate order of cytotoxicity to be: SA > SB > GmC (Fig. 7A). All the combined therapies elicited rather large extents of apoptosis (Fig. 7B). Interestingly, when treated with combined SC-2 the order of cytotoxicity changed to SC-2+SA > SC-2+GmC > SC-2+SB, consistent with the MTT assay (Table 3).

Now, the question arises “Could such non-spontaneous unidirectional transport be allowed to occur?” To resolve this problem, we performed a theoretical calculation using the Second Law of Thermodynamics (please be referred to Text S1) (Table 4, Table 5). Results in Table 6 indeed evidenced such a “Catcher-Pitcher Unidirectional Transport Mechanism” (Fig. 8, Fig. 9).

Finally, SC-2 exhibited appreciable water solubility (unpublished), implying that the feasible role of decoction in Traditional Chinese Medicinal preparations.

**Conclusions**

The pure peptidoglycan SC-2 obtained from *S. chinensis* fruits is nontoxic to the HepG2 cell line. SC-2 increases the transport and cytotoxicity of SC lignans by the “Catcher-Pitcher Unidirectional Transport Mechanism”, underlying the beneficial effect of SC-2 to improve the hepatoprotective effect. Physical chemically, the Second Law of Thermodynamics allows such a unidirectional transport phenomenon. More importantly, the pharmacodynamic behavior greatly improved by the combined therapy (SC-2+lignans) implies the decoction philosophy for preparation of the Traditional Chinese Medicine.

---

**Table 6.** The overall free energy changes during the transport of *S. chinensis* lignans from the extracellular into the intracellular compartment.*

| Parameters | ΔG₀,1 | ΔG₀,2 | ΔG₀,3 | ΔG₀,4 |
|------------|--------|--------|--------|--------|
| Free energy changes, KJ | −∞ | −2.572 | +0.059 | −∞ |
| Kₑq mol⁻¹ | Kₑq = Kₑq × e⁻x⁻⁶⁹ | 0.9980 | −0.0189 | +x⁻³ |
| Equation applied | Eq. 3–Eq. 6 | Eq. 7–Eq. 9 | Eq. 11, Eq. 12 | Eq. 13–Eq. 16 |
| Overall free energy change | ΔG₀,1+ΔG₀,2+ΔG₀,3+ΔG₀,4 = −∞ |

*Free energy changes = − RT/nKₑq, R = 8.314 JK⁻¹ mol⁻¹, T = 310 K.

**Kₑq** is a pseudo-equilibrium constant. K is the amount of outer membrane concentration defined in Table 5.

Value of ΔG₀ was exemplified by the largest value (of deoxychisandrin) among these three lignans (as referred to Table 2).

The value Kₑq in calculation of ΔG₀,4 is reality is not an equilibrium constant because reversible reaction does not occur in the intracellular degradation process. The value was estimated by the difference between the initial and the final conditions (be referred to text).

DOI 10.1371/journal.pone.0085165.s006
Supporting Information

Figure S1 HPLC, UV-Visible, ESI-MS and ESI-MS-MS analyses (top to bottom) of dibenzocyclooctadiene lignans isolated from *Schisandra chinensis* fruits. Gomisin C (GmC); deoxyschisandrin (SA); schisandrin B (SB). The molecular weights: gomisin C, 536.6; deoxyschisandrin, 416.5; and schisandrin B, 400.5, respectively. (TIF)

References

1. Day AJ, Prewett GD (2002) Hyaluronan-binding proteins: tying up the giant. J Biol Chem 277:4385–4388.
2. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528–539.
3. Janes KA, Calvo P, Alonso MJ (2001) Polysaccharide colloidal particles as delivery vectors for macromolecules. Adv Drug Deliv Rev 47: 83–97.
4. Liu M, Wu K, Mao X, Wu Y, Ouyang J (2010) Atrasugal polysaccharide improves insulin sensitivity in KKAY mice: regulation of PKB/GLUT4 signaling in skeletal muscle. J Rhozinopharmacol 127: 32–37.
5. Shih J, Tu L, Chen Y, Yue W, Wu P (2010) A method for the control and analysis of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J Pharmaceut Sci 4: 138–150.
6. Polyakov NE, Leshina TV, Meteleva ES, Dushkin AV, Konovaeva TA, et al. (2010) Kupert LD. Water soluble carboxymethyl conjugates with oligo- and polysaccharides synergize drug transport and efficacy. NSTI Nanotech 3: 312–315.
7. Victor R, Chauzy N, Gianni J, Cones SE, Kim JH, et al. (1999) Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int J Cancer 82: 77–83.
8. Kuang DM, Wu Y, Chen N, Cheng J, Zhang SM, et al. (2007) Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110: 587–595.
9. Yin SY, Lee YJ, Lee YK, Jung SE, Kim JH, et al. (2009) Gomisin N isolated from *Schisandra chinensis* significantly induced anti-proliferative and pro-apoptotic effects in hepatic carcinoma. Med Mec Rep 2: 725–732.
10. Ip SF, Mak DH, Li PC, Poon MK, Ko KM (1996) Effect of a lignan-enriched extract of *Schisandra chinensis* on aflatoxin B1 and cadmium chloride-induced hepatotoxicity in rats. Pharmacol Toxicol 78: 413–416.
11. Cyeng JC, Ki SM, Lijima K, Kobayashi T, Furuya M (2000) Clinical and pharmacological studies on liver diseases treated with Kangpo herbal medicine. Ann J Chin Med 39: 351–360.
12. Lu Y, Chen DF (2009) Analysis of *Schisandra chinensis* and *Schisandra sphenanthera*. J Chromatogr A 1216: 1890–1990.
13. Yin YZ, Yin W, Zhang X, Lu TL, Cai BC (2010) Development of an HPLC fingerprinting and component identification method of *Fructus schisandrae*. Acta Chromatogrphica 22: 609–621.
14. Xie Y, Hao H, Kang A, Liang Y, Xie T, et al. (2010) Integral pharmacokinetics of multiple lignan components in normal, CCl4-induced hepatic injury and correlations with hepatic injury biomarkers. J Ethnopharmacol 131: 290–299.
15. Kim SR, Lee MK, Koo KA, Kim SH, Sung SH, et al. (2004) Dibenzocyclooctadiene lignans from *Schisandra chinensis* protect primary cultures of rat cortical cells from glutamate-induced toxicity. J Neurosci Res 76: 397–405.
16. Min HY, Park EJ, Hong JY, Kang YJ, Kim SJ, et al. (2008) Anti-proliferative effects of dibenzocyclooctadiene lignans isolated from *Schisandra chinensis* in human cancer cells. Bioorg. Med Chem Lett 18: 523–526.
17. Foretov J, Hasek M, Sakuta T, Mori K, Higuchi R, et al. (1995) Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, human cancer cells. Bioorg. Med Chem Lett 22: 261–265.
18. Zhu M, Yeung TY, Lin KF, Li RC (2000) Improvement of phase I drug metabolism with *Schisandra chinensis* against CCl4 hepatotoxicity in a rat model. Planta Medica 66: 521–525.
19. Chang CY, Chen YL, Yang SC, Huang GC, Tai D, et al. (2009) Effect of schisandrin B and sesamin mixture on CCl4-induced hepatic oxidative stress in rats. Phytother Res 23: 251–256.
20. Chen Y, Tang J, Wang X, Sun F, Liang S (2012) An immunostimulatory polysaccharide (SCP-Ha) from the fruit of *Schisandra chinensis* (Turcz.) Baill. Int J Biol Macromol 50: 844–846.
21. Yan F, Zhang QY, Jiao L, Han T, Zhang H, et al. (2009) Synergistic hepatoprotective effect of Schisandraceae lignans with Atragenals polysaccharides on chronic liver disease in rats. Phytomedicine 16: 895–913.
22. Le Torre GL, Saitta M, Vlassis F, Pellicano T, Dugo G (2006) Direct determination of phenolic compounds in Sicilian wines by liquid chromatography with PDA and MS detection. Food Chem 94: 640–650.
23. Ko YB, Chen KC, Chyau CC, Chen CC, Guo JH, et al. (2005) Antioxidant capability of polysaccharides fractionated from submerge-cultured *Agaricus blazei* mycelia. J Agric Food Chem 53: 7052–7058.
24. Dubois M, Gilles KA, Hamilton JK, Reders PA, Smith F (1956) Colorimetric method for determination of sugars and related substances. Anal Chem 28: 350–356.
25. Peng CH, Chang CH, Peng RY, Chyau CC (2010) Improved membrane transport of astaxanthin by liposomal encapsulation. Eur J Pharm Biopharm 75: 154–161.
26. Kanohe Y, Ueno T, Tanaka T, Iwase H, Yamaguchi Y, et al. (2000) Pharmacokinetics and biodistribution of fluorescein labeled arabinogalactan in rats. Int J Pharmaceut 210: 39–68.
27. Tanaka T, Fujishima Y, Hanano S, Kano Y (2004) Intracellular disposition of polysaccharides in rat liver parenchymal and nonparenchymal cells. Int J Pharmaceut 286: 9–17.
28. Borgen AB, Calsen BM (2000) Cell death in denervated skeletal muscle is distinct from classical apoptosis. Anat Rec 58: 305–318.
29. Gavriel Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol* 119: 493–500.
30. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 240–243.
31. Welslauer DB (1962) Ultraviolet spectra of proteins and amino acids. Adv Protein Chem 17: 303–309.
32. Ma WH, Li Y, Huang H, Zhou P, Chen DF (2008) Schisandrinolamines A-G and related anti-HBV lignans from the fruits. Bioorg. Med Chem Lett 19: 4958–4962.
33. Gnabre J, Lisseck P, Bourne B, et al. (2010) Isolation of polysaccharides synergy of drug transport and efficacy. NSTI Nanotech 3: 312–315.
34. Gnecco J, Ulasi I, Chang TC, Lisseck P, Bourne B, et al. (2010) Isolation of lignans from *Schisandra chinensis* with anti-proliferative activity in human colorectal carcinoma: Structure-activity relationships. J Chromatogr B 878: 2693–2700.
35. Opletal L, Krenková M, Havlíčková P (2010) Phytotherapeutic aspects of *Schisandra sphenanthera*. Ceska Slov Farm 50: 219–224.
36. Dubois M, Gilles KA, Hamilton JK, Reders PA, Smith F (1956) Colorimetric method for determination of sugars and related substances. Anal Chem 28: 350–356.
37. Opletal L, Krenková M, Havlíčková P (2010) Phytotherapeutic aspects of *Schisandra sphenanthera*. Ceska Slov Farm 50: 219–224.
38. Lee IS, Jung KY, Oh SR, Park SH, Ahn KS, et al. (1999) Structure-activity relationships of lignans from *Schisandra chinensis* as platelet activating factor antagonists. Biol Pharm Bull 22: 265–267.
39. Chiu PY, Leung HY, Siu AH, Poon MK, Ko KM (2007) *Schisandra chinensis* decreases the sensitivity of mitochondria to calcium ion-induced permeability transition and protects against carbon tetrachloride toxicity in mouse livers. Biol Pharm Bull 30: 1108–1112.
40. Iwata H, Tsuchiya Y, Kadota S, Hirasaka A, Watabe T (2004) Identification and characterization of potent CYP3A4 inhibitors in *Schisandra* fruit extract. Drug Metab Dispos 32: 1531–1538.

Text S1 (DOC)

Author Contributions

Conceived and designed the experiments: CCP RYP. Performed the experiments: CCC SHH. Contributed reagents/materials/analysis tools: CHC HEW. Wrote the paper: CCC RYP.